Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.45 |
| ▸ | CNR2 | P34972 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.45 |
| ▸ | PPARD | Q03181 | 2/20 | 0.45 |
| ▸ | CNR1 | P21554 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitrogen SCHEMBL11130737 | 0.95 | ALDH1A1 (0.48) | ALDH1A1CYP3A4SMN1; SMN2TP53ALOX15 | |
| SCHEMBL10527833 | 0.93 | ALDH1A1 (0.47) | ALDH1A1CYP3A4SMN1; SMN2TP53ALOX15 | |
| SCHEMBL173301 | 0.86 | ALDH1A1 (0.64) | ALDH1A1CYP3A4SMN1; SMN2TP53ALOX15 | |
| Water SCHEMBL29179560 | 0.83 | ALDH1A1 (0.61) | ALDH1A1CYP3A4SMN1; SMN2TP53ALOX15 | |
| Bromide SCHEMBL8645583 | 0.83 | ALDH1A1 (0.61) | ALDH1A1CYP3A4SMN1; SMN2TP53ALOX15 | |
| Phosphine SCHEMBL28908227 | 0.83 | ALDH1A1 (0.61) | ALDH1A1CYP3A4SMN1; SMN2TP53ALOX15 | |
| SCHEMBL5569582 | 0.81 | ALDH1A1 (0.54) | ALDH1A1CYP3A4SMN1; SMN2TP53ALOX15 | |
| Hydrogen Peroxide SCHEMBL5496256 | 0.80 | ALDH1A1 (0.58) | ALDH1A1CYP3A4SMN1; SMN2TP53ALOX15 | |
| Hydrogen Peroxide SCHEMBL7816450 | 0.80 | ALDH1A1 (0.58) | ALDH1A1CYP3A4SMN1; SMN2TP53ALOX15 | |
| SCHEMBL10693711 | 0.78 | ALDH1A1 (0.56) | ALDH1A1CYP3A4SMN1; SMN2TP53ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1454 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108415221-B | Photosensitive resin composition and application thereof | 奇美实业股份有限公司 | 2023-07-28 | — | — | CN | claimed |
| EP-2168948-B1 | 2-AMINO-NICOTINAMIDE DERIVATIVES AND THEIR USE AS VEGF-RECEPTOR TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-05-07 | — | — | EP | claimed |
| US-20120184561-A1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-07-19 | — | — | US | claimed |
| JP-4837864-B2 | — | — | 2011-12-14 | — | — | JP | claimed |
| JP-4673977-B2 | — | — | 2011-04-20 | — | — | JP | claimed |
| EP-1874770-B1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-03-09 | — | — | EP | claimed |
| EP-1642567-B1 | Colouring composition comprising naphthoylene-benzimidazolium compound as direct dye, preparation and uses | OREAL (FR) | 2010-11-03 | — | — | EP | claimed |
| US-20100261726-A1 | TREATMENT OF AML | DE BONT EVELINE S J M | 2010-10-14 | — | — | US | claimed |
| US-20100130408-A1 | USE OF MODIFIED CYCLOSPORINS | KOHJIMA MOTOYUKI | 2010-05-27 | — | — | US | claimed |
| EP-2168948-A1 | 2-AMINO-NICOTINAMIDE DERIVATIVES AND THEIR USE AS VEGF-RECEPTOR TYROSINE KINASE INHIBITORS | Novartis AG (CH) | 2010-03-31 | — | — | EP | claimed |
| US-5137888-A | Side effect reduction | BAZZANO GAIL S (US) | 1992-08-11 | — | — | US | claimed |
| US-5034152-A | Liquid crystal 4-alkylbenzenethiols, ferroelectricity | CANON KABUSHIKI KAISHA (JP) | 1991-07-23 | — | — | US | claimed |
| US-5011944-A | Substituted α-pyrones | CIBA-GEIGY CORPORATION (US) | 1991-04-30 | — | — | US | claimed |
| EP-0254078-B1 | PYRAN DERIVATIVES | BASF Aktiengesellschaft (DE) | 1991-02-06 | — | — | EP | claimed |
| EP-0332847-A2 | Composition for preventing graying of the hair and restoring grayed hair to its natural color | LION CORPORATION (JP) | 1989-09-20 | — | — | EP | claimed |
| WO-1989006234-A1 | N,N-SUBSTITUTED AMINES AND USE THEREOF IN HAIR GROWTH PROMOTION | BAZZANO GAIL S (US) | 1989-07-13 | — | — | WO | claimed |
| US-4287201-A | CONTAINING A 2-(SUBSTITUTED PHENYLIMINO)IMIDAZOLIDINE COMPOUND | MERCK & CO., INC. (US) | 1981-09-01 | — | — | US | claimed |
| US-4198205-A | SULFONIC ACID-FREE DISPERSE DYES | BASF AKTIENGESELLSCHAFT (DE) | 1980-04-15 | — | — | US | claimed |
| US-4196284-A | FUGNCICDES | FMC CORPORATION (US) | 1980-04-01 | — | — | US | claimed |
| US-3962210-A | CURING AGENTS, POLYMERIZATION INITIATORS | PENNWALT CORPORATION (US) | 1976-06-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130408-A1 | USE OF MODIFIED CYCLOSPORINS | CHP1, SERPINA6, FKBP2 | ALDH1A1 3427/4885CYP3A4 1035/4885SMN1; SMN2 3951/4885 |
| US-20120184561-A1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | MAP3K10, MAP3K20, MAP3K9 | ALDH1A1 3213/4885CYP3A4 3394/4885SMN1; SMN2 4309/4885 |
| US-20100261726-A1 | TREATMENT OF AML | MCL1, TOP2A, TOP2B | ALDH1A1 1582/4885CYP3A4 930/4885SMN1; SMN2 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.